Can We Reverse Aging in the Eye? The First Human Trial Is Underway

What if the cells in your eye could be made younger?

Not younger in a cosmetic, marketing-speak sense. Younger at the molecular level. Younger in a way that restores how they function, how they communicate, and how they survive.

That is exactly what a team of scientists is testing right now. In March 2026, the first patients enrolled in a clinical trial designed to rejuvenate damaged retinal cells using a technology called epigenetic reprogramming. It is the first time this approach has been tried in a living human eye. And it could change how we think about aging, vision loss, and what is possible for conditions like glaucoma.

Here is what you need to know.

What Is Epigenetic Reprogramming, and Why Does It Matter for Your Eyes?

To understand what this trial is doing, you need a quick primer on how aging works at the cellular level.

Every cell in your body carries the same DNA. But not every cell uses the same genes. What determines which genes are active in a given cell is something called the epigenome. Think of DNA as a massive instruction manual. The epigenome is the set of bookmarks and sticky notes that tell each cell which pages to read.

As you age, those bookmarks get shuffled. Genes that should be active go quiet. Genes that should be quiet start firing. The cell does not lose its instructions. It loses its ability to follow them correctly. This is one of the reasons cells decline with age: not because the blueprint is damaged, but because the cell can no longer read it properly.

Epigenetic reprogramming is the idea that you can reset those bookmarks. You can tell a cell, "Go back to the way you read your instructions when you were younger." The tools for doing this come from a Nobel Prize-winning discovery by Shinya Yamanaka, who showed in 2006 that four specific proteins can reprogram adult cells back to a stem cell-like state.

The trick is doing this partially. Full reprogramming turns a cell into a stem cell, which is not what you want inside a living eye. Partial reprogramming aims to wind back the epigenetic clock just enough to restore youthful function without changing the cell's identity. The cell stays a retinal ganglion cell. It just starts acting like a younger one.

How Did We Get Here? The Mouse Studies That Started It All

The groundwork for this trial was laid in a landmark 2020 study published in Nature by a team at Harvard Medical School led by Yuancheng Lu and David Sinclair.

The researchers used a modified virus to deliver three of the four Yamanaka factors, known as OCT4, SOX2, and KLF4 (or OSK for short), into the retinal ganglion cells of mice. These are the nerve cells in the back of the eye that send visual signals to the brain. They are the cells that die in glaucoma.

The results were striking. In mice with glaucoma-like optic nerve damage, OSK restored youthful DNA methylation patterns, promoted nerve regeneration, and reversed vision loss. In aged mice without glaucoma, it improved vision too. The beneficial effects required specific enzymes called TET1 and TET2, confirming that the mechanism worked through genuine epigenetic reprogramming, not some other pathway.

A follow-up study published in 2023 by Karg, Lu, and colleagues pushed the findings further. They showed that just two months of OSK expression fully restored impaired vision in glaucomatous mice, and the benefit lasted for up to 11 months with continued expression. Importantly, mice that received continuous OSK for 21 months showed no adverse effects on retinal structure or body weight. That long-term safety data was critical for moving toward human trials.

The ER-100 Trial: What Is Actually Happening Right Now?

In January 2026, the FDA cleared Life Biosciences to begin a Phase 1 clinical trial of ER-100, their epigenetic reprogramming therapy, in human patients with optic nerve conditions. The trial started recruiting in March 2026.

Here is what the trial looks like. ER-100 uses a modified adeno-associated virus (AAV) to deliver the OSK factors directly into retinal cells through an injection into the eye. Once delivered, the genes are activated by having patients take low doses of the antibiotic doxycycline for eight weeks. This acts as a genetic "on switch" that controls when the reprogramming factors are active. When the doxycycline stops, the reprogramming stops.

The trial (NCT07290244) is enrolling up to 18 participants in two groups: 12 with open-angle glaucoma and 6 with non-arteritic anterior ischemic optic neuropathy (NAION), a condition where sudden blood flow loss damages the optic nerve. Both conditions involve retinal ganglion cell damage and vision loss.

As a Phase 1 trial, the primary goal is safety. The researchers are testing whether ER-100 is well tolerated, monitoring for inflammation, changes in eye pressure, and any structural changes in the retina. But they are also measuring visual acuity, visual fields, contrast sensitivity, and retinal nerve fiber thickness as secondary outcomes. In other words, they will know if vision changes.

Participants will be followed for up to five years. The first results could come by late 2026 or early 2027.

Where Should You Set Your Expectations?

Here is where you pump the brakes.

This is a Phase 1 trial. That means 18 people, not thousands. The primary question is "Is this safe?" not "Does this restore vision?" If the trial goes perfectly, it will still take years before this therapy could become widely available. Phase 2 and Phase 3 trials would need to follow, each larger and longer.

The mouse data is genuinely exciting, but mouse eyes are not human eyes. What works beautifully in a laboratory model does not always translate to human biology. The doses, the delivery method, and the duration of effect may all be different in people.

That said, several things make this trial particularly noteworthy. The preclinical data is unusually strong: published in Nature, replicated in follow-up studies, and showing sustained benefit over months. The safety profile in animals has been encouraging across long time periods. And the fact that the FDA cleared the trial means regulators reviewed the evidence and considered it sufficient to proceed.

For people with glaucoma or optic nerve damage, this is one of the most hopeful developments in years. It is not a reason to change your current care. It is a reason to pay attention.

What Does This Mean for You?

If you have glaucoma or are concerned about age-related vision changes, here is the practical takeaway.

This trial represents a new category of therapy for the eye. Rather than lowering eye pressure (the current standard of care for glaucoma) or replacing damaged cells, epigenetic reprogramming aims to rejuvenate the cells you still have. It is not a replacement for existing treatment. It is an entirely different approach that targets a different part of the problem: the aging of the cells themselves.

Your current care matters. Eye pressure management, regular check-ups, and working closely with your ophthalmologist remain the foundation. Nothing about this trial changes that.

But this is worth watching. The idea that aging in the eye might be, at least partially, reversible is no longer theoretical. It is being tested in people right now.

The Bigger Picture

The story of epigenetic reprogramming and the eye is really a story about how we think about aging itself. For decades, vision loss from conditions like glaucoma was considered a one-way process. Once those retinal ganglion cells were gone, they were gone.

This research challenges that assumption. It suggests that cells may retain a "backup copy" of their youthful programming that can be accessed and restored. If that holds up in humans, the implications extend far beyond ophthalmology.

In the meantime, supporting the cellular health of your eyes today is something you can do right now. For people who want to take a proactive approach to their vision, supporting cellular energy in the eye with a targeted supplement like Sight Guard is one way to complement your existing care while the science of tomorrow continues to develop.

References

1. Lu Y, Brommer B, Tian X, et al. Reprogramming to recover youthful epigenetic information and restore vision. Nature. 2020;588(7836):124-129.

DOI: 10.1038/s41586-020-2975-4

2. Karg MM, Lu YR, Refaian N, et al. Sustained vision recovery by OSK gene therapy in a mouse model of glaucoma. Cellular Reprogramming. 2023;25(6):288-299.

DOI: 10.1089/cell.2023.0074

3. Rizzo JF, Shah MP, Krasniqi D, et al. The role of epigenetics in accelerated aging: a reconsideration of later-life visual loss after early optic neuropathy. J Neuroophthalmol. 2024;44(1):16-21.

DOI: 10.1097/WNO.0000000000002041

4. Life Biosciences. FDA clearance of IND application for ER-100 in optic neuropathies. January 28, 2026. https://www.lifebiosciences.com/life-biosciences-announces-fda-clearance-of-ind-application-for-er-100-in-optic-neuropathies/

5. ClinicalTrials.gov. A Phase 1 single dose study to evaluate the safety and tolerability of ER-100 in optic neuropathies. NCT07290244. https://clinicaltrials.gov/study/NCT07290244

FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Medical Disclaimer: The information provided in this article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.